Novartis in Society Integrated Report 2022

Performance indicators

Deliver high-value medicines performance indicators

Deliver high-value medicines performance indicators1

 

2022

2021

2020

Projects entering development pipeline 2

5

7

6

Ongoing Phase III programs 3

44

54

44

US FDA breakthrough therapy designations 4

1

3

2

Major submissions (US, EU, JP, China) 5

24

34

13

Major approvals (US, EU, JP, China) 5

23

21

26

New molecular entity (NME) approvals 6

1

2

4

1

Includes Innovative Medicines and Sandoz biosimilars only

2

Includes projects having achieved first patient, first visit (FPFV) in confirmatory development (incl. projects entering confirmatory development from an acquisition or in-licensing). Figures shown for the year 2021 and 2020 consider projects applying the former methodology, i.e. projects entering confirmatory development from internal R&D activities. FPFV has occurred in post-proof-of-concept stage after NIBR.

3

Includes projects with FPFV in a Phase III study but not yet filed in the US, EU, Japan or China

4

Number of breakthrough therapy designations granted by the US Food and Drug Administration for therapies under development by Novartis

5

Includes small molecules or biologics; new fixed-dose combinations of existing APIs; and new target indications, defined as new disease or new line of treatment (e.g., first line vs. second line)

6

Includes NMEs such as small molecules, biologics; in the EU, new fixed-dose combinations of existing APIs

Patient health and safety performance indicators

Patient health and safety performance indicators

 

2022

2021

2020

GxP audits

 

 

 

Total audits executed

1 392

1 419

903

Internal 1

134

125

111

External 2

1 258

1 294

792

Regulatory authorities

 

 

 

Total inspections

139

126

126

Inspections found to be acceptable (%)

100

99.2

99.2

US FDA

 

 

 

FDA inspections

10

10

6

FDA warning letters

0

0

0

FDA Form 483

7

5

1

US FDA sponsor inspections

 

 

 

Inspections related to clinical trial management and pharmacovigilance

1

3

1

Number of FDA VAI (voluntary action indicated) classifications

0

0

0

Number of FDA OAI (official action indicated) classifications

0

0

0

Recalls

 

 

 

Total recalls

19

27

27

Class I recalls

0

3

1

Class II recalls

16

20

21

US FDA

 

 

 

FDA recalls

1

1

0

1

Total number of audits performed on facilities owned by Novartis

2

Total number of audits performed on GxP suppliers to Novartis

Supply chain performance indicators

Supply chain performance indicators

 

2022

2021

2020

Suppliers risk-assessed by Third-Party Risk Management (TPRM) 1

 

 

 

Number of suppliers risk-assessed by TPRM

11 097

12 064

8 448

Suppliers assessed by risk area 2

 

 

 

Anti-bribery

1 553

2 303

2 014

Animal welfare 3

18

9

10

Health, safety and environment

296

477

315

Information security and data privacy

6 694

5 668

3 174

Labor rights

5 379

6 755

4 635

Quality GmP 4

594

848

561

Actions taken

 

 

 

Suppliers audited

86

85

35

Suppliers with remediation action agreed 5

384

912

521

Supplier engagements stopped due to risk assessment outcomes

17

37

120

1

Assessment is done on new suppliers and new products, services or sites from existing suppliers. Not all suppliers trigger risk assessments. Figures do not include GxP audits (see “Patient health and safety performance indicators”).

2

Reflects risk assessments conducted on suppliers. One supplier can trigger more than one assessment depending on the risk areas involved.

3

Increased primarily due to re-assessments and rescheduled assessments following the COVID-19 pandemic

4

Risk area “Quality GmP” de-scoped from November 2022 onwards

5

Decreased due to fewer medium- and high-risk cases

Environment performance indicators

Environment performance indicators1

 

2022

2021

2020

Energy use - on site and purchased (million GJ)

9.9

9.8

10.9

Greenhouse gas (GHG) emissions (1 000 tCO2e)

 

 

 

Total Scope 1 emissions

347.2

352.8

378.3

Combustion and process

256.4

264.1

287.0

Vehicles

90.8

88.7

91.3

Total Scope 2 emissions (market based)

154.9

292.7

335.5

Total Scope 2 emissions (location based) 2

399.2

439.4

487.2

Total Scope 1 and Scope 2 (excluding offsets)

502.1

645.5

713.8

Total Scope 3 emissions 3

8 770.0

7 290.4

7 268.8

Purchased goods and services

7 350.6

5 958.4

5 754.0

Capital goods

301.2

303.8

278.7

Business travel 4

93.0

36.2

68.3

Use of sold products 5

260.1

199.2

163.9

Total Scope 1, Scope 2 and Scope 3 emissions

9 272.1

7 935.9

7 982.6

Carbon offsets 6

30.7

–34.7

33.6

GHG emissions intensity (tCO2e)

 

 

 

Scope 1 and Scope 2 per million USD sales

9.9

12.3

14.4

Scope 1 and Scope 2 per FTE

4.9

6.1

6.6

VOCs (t)

 

 

 

Halogenated volatile organic compounds

0.8

0.8

11.6

Non-halogenated volatile organic compounds

313.1

304.7

443.0

Water (million m3)

 

 

 

Total water withdrawal 7

52.1

47.6

54.7

Surface water

7.9

6.5

7.1

Groundwater

36.8

35.3

41.7

Third-party water

7.4

5.8

5.9

Total water discharged 8

49.6

46.6

54.5

Water consumption 9

7.5

7.7

8.4

Operational waste (1 000 t)

 

 

 

Total waste generated

97.0

103.6

130.6

Total non-hazardous waste

63.6

66.7

68.7

Total hazardous waste

33.4

36.9

61.9

Total waste diverted from disposal

69.5

73.4

88.6

Non-hazardous waste recycled

53.4

56.0

59.9

Hazardous waste recycled

16.1

17.4

28.7

Total waste directed to disposal

27.5

30.2

42.1

Non-hazardous waste not recycled

10.2

10.7

8.8

Hazardous waste not recycled

17.3

19.5

33.3

1

Other than where indicated, environmental data for the current year are based on actuals for January-September and estimates for October-December (to be updated with actuals in 2023 in our annual Novartis Environmental Sustainability datasheet). Any significant deviations are restated the following year in the Novartis in Society Integrated Report. Previous years’ data reflect only actuals.

2

Using location based emission factors published in 2014 or 2015 depending on geography and data source. We plan to update the factors in the future reporting periods with the latest available ones.

3

Scope 3 emissions are reported in accordance with the GHG Protocol. Only the Scope 3 categories which are assured are separately disclosed. The total scope 3 emissions figure includes all categories. Our Scope 3 emissions increased by 20% from the prior year, driven primarily by purchased goods and services and, to a smaller extent, by increased business travel following the pandemic

4

Data includes indirect emissions from air travel, train travel, car rentals and hotel stays. The indicator is calculated using 12-month actual data.

5

For all disclosed years, the calculation for our inhalers is based on the IPCC 2015 GHG emission factor and assumes all hydrofluorocarbon (HFC) gas used in the production process is released upon use of the inhalers. We are in the process of determining if a portion of this gas is released during manufacturing and whether a portion also remains in the inhaler after its use, which would therefore need to be excluded from our calculation of Scope 3 use of sold products emissions.

6

Carbon offsets are based on data provided by third parties. For further details, please see our Reporting Criteria document.

7

Water withdrawals includes water used for cooling and returned to the environment without the need for additional treatment

8

Water consumption and non-contact water withdrawn from the environment for cooling and returned directly to the environment after use.

9

Water discharged via treatment and water lost

People performance indicators

People performance indicators

 

2022

2021

2020

Headcount 1

105 533

108 514

110 738

Full-time equivalent positions 1

101 703

104 323

105 794

Percentage turnover: voluntary / overall

9 / 15

8 / 13

5 / 10

Percentage of hires: internal / external

66 / 34

62 / 38

58 / 42

Annual learning hours per employee 2

42.4

52.1

53.2

Representation of nationalities: overall / management 3

147 / 118

143 / 115

142 / 113

Employees represented by an employee representative body or covered by a collective bargaining agreement (%) 4

48

47

46

Health and safety

 

 

 

Lost-time injury and illness rate (per 200 000 hours worked):
Novartis employees / Third-party personnel

0.16 / 0.20

0.14 / 0.05

0.12 / 0.20

Total recordable case rate (per 200 000 hours worked) 5:
Novartis employees / Third-party personnel

0.31 / 0.28

0.25 / 0.13

0.23 / 0.30

Fatalities: Novartis employees / Third-party personnel / Contractors

0 / 0 / 0

0 / 0 / 0

0 / 0 / 1

Gender representation (% female / % male) 6

 

 

 

Overall headcount

51 / 49

51 / 49

50 / 50

Hires

52 / 48

52 / 47

52 / 48

Promotions

53 / 47

55 / 45

52 / 48

Overall turnover

49 / 51

50 / 50

49 / 51

Voluntary turnover

51 / 49

51 / 49

52 / 48

Board of Directors

31 / 69

31 / 69

29 / 71

Executive Committee of Novartis

27 / 73

25 / 75

23 / 77

Novartis Top Leaders 7

39 / 61

38 / 62

33 / 67

Senior management

41 / 59

39 / 61

39 / 61

Middle management

48 / 52

47 / 53

46 / 54

Overall management 3

47 / 53

46 / 54

45 / 55

Entry-level positions

52 / 48

52 / 48

52 / 48

Revenue-producing roles 8

51 / 49

51 / 49

50 / 50

STEM roles 9

46 / 54

46 / 54

46 / 54

Gender representation by contract type (female / male)

 

 

 

Permanent

52 311 / 49 549

53 509 / 51 497

53 729 / 53 096

Temporary

1 881 / 1 709

1 854 / 1 539

1 935 / 1 629

Full time

47 631 / 50 084

48 618 / 51 904

48 472 / 53 507

Part-time

6 573 / 1 175

6 755 / 1 133

7 204 / 1 219

Number of employees by region, by contract type (permanent / temporary)

 

 

 

Asia-Pacific

27 197 / 486

28 229 / 420

27 711 / 300

Europe, Middle East and Africa

54 892 / 2 943

55 362 / 2 752

56 852 / 3 016

Latin America

4 508 / 92

5 101 / 127

5 092 / 157

North America

15 263 / 69

16 314 / 94

17 170 / 91

1

“Headcount” reflects the total number of employees in payroll systems. “Full-time equivalent positions” adjusts headcount for employees working less than 100%.

2

Since 2022, Novartis reports training hours for internal employees only

3

Management defined by Global Job Level Architecture and Novartis Top Leaders

4

Generally non-management employees

5

Data include all work-related injuries and illnesses, whether leading to lost time or not.

6

Fewer than 0.5% of employees have unknown classification. Some indicators do not add up to 100%.

7

Novartis Top Leaders comprise the approximately 300 most senior managers at Novartis, including the Executive Committee of Novartis.

8

Revenue-producing roles defined as the sum of the following Novartis job families: BD&L and strategic planning; commercial and general; market access; marketing and sales.

9

STEM roles defined as the sum of the following Novartis job families: R&D; Technical Operations; Information Technology & Technology Transformation.

Access to healthcare performance indicators

Access to healthcare performance indicators

 

2022

2021

2020

Overall patients reached (millions)

 

 

 

Patients reached through access approaches 1

54.6

56.2

66.4

Sustain­ability-linked bond (September 23, 2020 – September 23, 2028)

 

 

 

Patients reached with strategic innovative therapies

1 197 352

947 699

695 669

Patients reached through flagship programs

31 157 087

32 695 224

43 912 152

1

Includes patients reached with medicines through Novartis Global Health, as well as patients reached through support programs, emerging market brands and donations

Health system strengthening performance indicators

Novartis Global Health
Health system strengthening performance indicators1

 

2022

2021

2020

Health educators trained

4 477

2 827

671

Healthcare providers trained

12 035

10 719

12 648

Points of service provision 2

1 313

4 365

5 902

People reached at points of service provision

979 755

360 356

486 642

Awareness events held

297 700

412 872

424 878

People reached at awareness events

12 960 922

9 678 360

8 048 360

1

Data reflect the full scope of access approaches managed by the Novartis Global Health organization.

2

Points of service provision include facilities and health camps where healthcare services are provided.

Animals needed for research

Animals needed for research1

 

2022

2021

2020

Total

332 668

353 772

410 359

Rodents

261 256

265 111

312 332

% of total

78.5

74.9

76.1

Zebrafish

70 826

88 229

97 596

% of total

21.3

24.9

23.8

Other species

586

432

431

% of total

0.2

0.1

0.1

1

Data refer to animals needed for internally conducted animal studies for Novartis. For data on animals needed for both internally and externally conducted animal studies, please see our corporate website.

Ethical business practices performance indicators

Ethical business practices performance indicators

 

2022

2021

2020

Code of Ethics

 

 

 

Employees trained and certified (%) 1

98

98

98

Grievance indicators: SpeakUp Office - central matters 2, 3

 

 

 

Misconduct cases reported

385

174

157

Total allegations 4

544

296

284

Allegations substantiated 5

257

137

118

Total allegations substantiated per category (%): SpeakUp Office - central matters

 

 

 

Fraud/asset misappropriation

7

13

7

Expense fraud

2

4

2

Books and records, accounting irregularities

0

0

1

Improper professional practices

12

20

14

Bribery, kickbacks

0

2

1

Discrimination and sexual harassment

3

8

11

Retaliation

1

5

3

Other employee relations issues

5

14

18

Conflict of interest

5

12

13

IT security breach

41

4

4

Quality assurance / data integrity

2

3

8

Data privacy

12

3

2

Antitrust, fair competition

0

1

1

Company confidential / trade secret information

1

2

4

Other

9

9

11

Dismissals and resignations related to misconduct

116

62

101

1

Active Novartis employees with an email address, trained via e-learning.

2

A central matter applies to issues where a senior leader or manager is involved, or issues which may have a potentially disruptive reputational impact. Also, central matters can involve sexual harassment, discrimination, retaliation and issues with significant financial impact.

3

The number of misconduct cases, allegations reported/substantiated, and dismissals/resignations may change year-on-year as matters may be reassessed in the course of the case life cycle. As a result, we may restate data from previous years.

4

The number of allegations is higher than the actual number of cases as a case can have more than one allegation.

5

“Allegations substantiated” and “total allegations substantiated per category” may include allegations from previous years. Whereas “misconduct cases reported” and “total allegations” refer to allegations reported within each calendar year.

Download all performance indicators here

 

ESG performance indicators 2022

42 kB

Topic filter

Results